238 related articles for article (PubMed ID: 30388073)
1. Comparative effectiveness of secukinumab and adalimumab in ankylosing spondylitis as assessed by matching-adjusted indirect comparison.
Maksymowych WP; Strand V; Nash P; Yazici Y; Thom H; Hunger M; Kalyvas C; Gandhi KK; Porter B; Jugl SM
Eur J Rheumatol; 2018 Dec; 5(4):216-223. PubMed ID: 30388073
[TBL] [Abstract][Full Text] [Related]
2. Secukinumab Versus Adalimumab for Psoriatic Arthritis: Comparative Effectiveness up to 48 Weeks Using a Matching-Adjusted Indirect Comparison.
Nash P; McInnes IB; Mease PJ; Thom H; Hunger M; Karabis A; Gandhi K; Mpofu S; Jugl SM
Rheumatol Ther; 2018 Jun; 5(1):99-122. PubMed ID: 29605841
[TBL] [Abstract][Full Text] [Related]
3. Secukinumab 150/300 mg Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis: 3-Year Results from the Phase 3 MEASURE 3 Study.
Pavelka K; Kivitz AJ; Dokoupilova E; Blanco R; Maradiaga M; Tahir H; Wang Y; Porter BO; Stefanska A; Richards HB; Rohrer S;
ACR Open Rheumatol; 2020 Feb; 2(2):119-127. PubMed ID: 31957970
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of secukinumab in Asian patients with active ankylosing spondylitis: 52-week pooled results from two phase 3 studies.
Wei JC; Baeten D; Sieper J; Deodhar A; Bhosekar V; Martin R; Porter B
Int J Rheum Dis; 2017 May; 20(5):589-596. PubMed ID: 28544533
[TBL] [Abstract][Full Text] [Related]
5. Achievement of Remission Endpoints with Secukinumab Over 3 Years in Active Ankylosing Spondylitis: Pooled Analysis of Two Phase 3 Studies.
Baraliakos X; Van den Bosch F; Machado PM; Gensler LS; Marzo-Ortega H; Sherif B; Quebe-Fehling E; Porter B; Gaillez C; Deodhar A
Rheumatol Ther; 2021 Mar; 8(1):273-288. PubMed ID: 33351179
[TBL] [Abstract][Full Text] [Related]
6. Budget impact analysis of secukinumab versus adalimumab in the treatment of ankylosing spondylitis.
Purmonen T; Törmälehto S; Wahlman H; Puolakka K
J Med Econ; 2019 Feb; 22(2):151-157. PubMed ID: 30474450
[TBL] [Abstract][Full Text] [Related]
7. Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3.
Pavelka K; Kivitz A; Dokoupilova E; Blanco R; Maradiaga M; Tahir H; Pricop L; Andersson M; Readie A; Porter B
Arthritis Res Ther; 2017 Dec; 19(1):285. PubMed ID: 29273067
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the Effects of Secukinumab and Adalimumab Biosimilar on Radiographic Progression in Patients with Ankylosing Spondylitis: Design of a Randomized, Phase IIIb Study (SURPASS).
Baraliakos X; Østergaard M; Gensler LS; Poddubnyy D; Lee EY; Kiltz U; Martin R; Sawata H; Readie A; Porter B;
Clin Drug Investig; 2020 Mar; 40(3):269-278. PubMed ID: 31983056
[TBL] [Abstract][Full Text] [Related]
9. Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis.
Baeten D; Sieper J; Braun J; Baraliakos X; Dougados M; Emery P; Deodhar A; Porter B; Martin R; Andersson M; Mpofu S; Richards HB; ;
N Engl J Med; 2015 Dec; 373(26):2534-48. PubMed ID: 26699169
[TBL] [Abstract][Full Text] [Related]
10. Impact of baseline C-reactive protein levels on the response to secukinumab in ankylosing spondylitis: 3-year pooled data from two phase III studies.
Braun J; Deodhar A; Landewé R; Baraliakos X; Miceli-Richard C; Sieper J; Quebe-Fehling E; Martin R; Porter B; Gandhi KK; van der Heijde D;
RMD Open; 2018; 4(2):e000749. PubMed ID: 30564451
[TBL] [Abstract][Full Text] [Related]
11. A cost per responder analysis of secukinumab vs adalimumab for the treatment of ankylosing spondylitis from the Korean perspective.
Kim D; Kim H; Cho S; Park MC
Int J Rheum Dis; 2019 Sep; 22(9):1630-1637. PubMed ID: 31215166
[TBL] [Abstract][Full Text] [Related]
12. Matching-Adjusted Indirect Comparison of the 52-Week Efficacy of Bimekizumab Versus Secukinumab and Ixekizumab for the Treatment of Radiographic Axial Spondyloarthritis.
Maksymowych WP; Thom H; Mørup MF; Taieb V; Willems D; Lyris N; Gaffney K
Rheumatol Ther; 2024 Jun; ():. PubMed ID: 38916823
[TBL] [Abstract][Full Text] [Related]
13. Secukinumab provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: 3-year results from the phase III trial, MEASURE 2.
Marzo-Ortega H; Sieper J; Kivitz A; Blanco R; Cohen M; Delicha EM; Rohrer S; Richards H
RMD Open; 2017; 3(2):e000592. PubMed ID: 29435364
[TBL] [Abstract][Full Text] [Related]
14. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.
McLeod C; Bagust A; Boland A; Dagenais P; Dickson R; Dundar Y; Hill RA; Jones A; Mujica Mota R; Walley T
Health Technol Assess; 2007 Aug; 11(28):1-158, iii-iv. PubMed ID: 17651658
[TBL] [Abstract][Full Text] [Related]
15. Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 Study.
Sieper J; Deodhar A; Marzo-Ortega H; Aelion JA; Blanco R; Jui-Cheng T; Andersson M; Porter B; Richards HB;
Ann Rheum Dis; 2017 Mar; 76(3):571-592. PubMed ID: 27582421
[TBL] [Abstract][Full Text] [Related]
16. Secukinumab and Sustained Reduction in Fatigue in Patients With Ankylosing Spondylitis: Long-Term Results of Two Phase III Randomized Controlled Trials.
Kvien TK; Conaghan PG; Gossec L; Strand V; Østergaard M; Poddubnyy D; Williams N; Porter B; Shete A; Gilloteau I; Deodhar A
Arthritis Care Res (Hoboken); 2022 May; 74(5):759-767. PubMed ID: 33227175
[TBL] [Abstract][Full Text] [Related]
17. One-Year Treatment Outcomes of Secukinumab Versus Tumor Necrosis Factor Inhibitors in Spondyloarthritis: Results From Five Nordic Biologic Registries Including More Than 10,000 Treatment Courses.
Glintborg B; Lindström U; Giuseppe DD; Provan SA; Gudbjornsson B; Hetland ML; Michelsen B; Wallman JK; Aaltonen K; Hokkanen AM; Nordström D; Jørgensen TS; Hansen RL; Geirsson AJ; Grøn KL; Krogh NS; Askling J; Kristensen LE; Jacobsson LTH;
Arthritis Care Res (Hoboken); 2022 May; 74(5):748-758. PubMed ID: 33253491
[TBL] [Abstract][Full Text] [Related]
18. Secukinumab and Sustained Improvement in Signs and Symptoms of Patients With Active Ankylosing Spondylitis Through Two Years: Results From a Phase III Study.
Marzo-Ortega H; Sieper J; Kivitz A; Blanco R; Cohen M; Martin R; Readie A; Richards HB; Porter B;
Arthritis Care Res (Hoboken); 2017 Jul; 69(7):1020-1029. PubMed ID: 28235249
[TBL] [Abstract][Full Text] [Related]
19. Comparative effectiveness of secukinumab and etanercept in biologic-naïve patients with psoriatic arthritis assessed by matching-adjusted indirect comparison.
Mease P; Choy E; Nash P; Kalyvas C; Hunger M; Pricop L; Gandhi KK; Jugl SM; Thom H
Eur J Rheumatol; 2019 Jul; 6(3):113-121. PubMed ID: 31364979
[TBL] [Abstract][Full Text] [Related]
20. Long-term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis: 5-year results from the phase III MEASURE 1 extension study.
Baraliakos X; Braun J; Deodhar A; Poddubnyy D; Kivitz A; Tahir H; Van den Bosch F; Delicha EM; Talloczy Z; Fierlinger A
RMD Open; 2019; 5(2):e001005. PubMed ID: 31565244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
